AbCellera Biologics (ABCL) Other Non-Current Assets (2020 - 2026)

AbCellera Biologics' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $69.1 million for Q1 2026.

• Quarterly Other Non-Current Assets rose 12.3% year-over-year to $69.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.1 million (up 12.3% YoY) and the FY2025 annual result came in at $51.9 million, down 46.19% from the prior year.
• Other Non-Current Assets was $69.1 million for Q1 2026 at AbCellera Biologics, up from $51.9 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $134.2 million in Q3 2024 and bottomed at $25.0 million in Q2 2022.
• A 5-year average of $73.0 million and a median of $69.1 million in 2026 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 354.43% — and 2025, when it sank 60.46%.
• AbCellera Biologics' Other Non-Current Assets stood at $28.1 million in 2022, then jumped by 235.39% to $94.2 million in 2023, then increased by 2.43% to $96.5 million in 2024, then slumped by 46.19% to $51.9 million in 2025, then jumped by 33.09% to $69.1 million in 2026.
• Business Quant data shows ABCL's Other Non-Current Assets at $69.1 million in Q1 2026, $51.9 million in Q4 2025, and $53.1 million in Q3 2025.